Congo vs Cote d'Ivoire: Statin use vs. average non-HDL cholesterol levels
Congo
2.8
in 2018
Cote d'Ivoire
2.8
in 2018
Congo rank
163rd
Cote d'Ivoire rank
163rd
Statin use vs. average non-HDL cholesterol levels over time
- Congo
- Cote d'Ivoire
How they compare
Congo currently reports 2.8 against 2.8 in Cote d'Ivoire, a difference of 0.
The two have swapped places 1 time across 39 shared years of data; in 1980 it was Congo ahead.
Congo ranks 163rd and Cote d'Ivoire ranks 163rd of 191 countries.
Congo has averaged higher in every one of the 4 decades both report.
Head to head by decade
| Decade | Congo | Cote d'Ivoire | Difference | Ahead |
|---|---|---|---|---|
| 1980s | 2.88 | 2.6 | 0.28 | Congo |
| 1990s | 2.9 | 2.7 | 0.2 | Congo |
| 2000s | 2.9 | 2.72 | 0.18 | Congo |
| 2010s | 2.86 | 2.8 | 0.0556 | Congo |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher statin use vs. average non-hdl cholesterol levels, Congo or Cote d'Ivoire?
- Congo, at 2.8 against 2.8 in Cote d'Ivoire as of 2018.
- What is the difference in statin use vs. average non-hdl cholesterol levels between Congo and Cote d'Ivoire?
- 0, with Congo ahead.
- How many years of comparable data are there for Congo and Cote d'Ivoire?
- 39 years are reported by both, from 1980 to 2018.
- How do Congo and Cote d'Ivoire rank globally for statin use vs. average non-hdl cholesterol levels?
- Congo ranks 163rd and Cote d'Ivoire ranks 163rd of 191 countries.
- Where does this data come from?
- World Health Organization - Global Health Observatory (2026) – with minor processing by Our World in Data, published as Statin use vs. average non-HDL cholesterol levels. Statizoid refreshes it automatically from the source and publishes the full history for both places.
Individual pages
About this data
The use of statins in the population. This is compared to average non-HDL cholesterol levels, in mmol/L. Statins are a type of drug that reduce non-HDL cholesterol levels, and are used to treat and prevent cardiovascular diseases in people at heightened risk. Their usage is measured in Defined Daily Doses, per 1,000 people.